Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial

被引：1

作者：

Aranda, E. ^{[1
]}

Ia-Alfonso, P. Garc ' ^{[2
]}

Benavides, M. ^{[3
]}

Sanchez-Ruiz, A. ^{[4
]}

Guillen-Ponce, C. ^{[5
]}

Safont, M. J. ^{[6
]}

Alcaide, J. ^{[7
]}

Gomez, A. ^{[1
]}

Lopez, R. ^{[8
]}

Manzano, J. L. ^{[9
]}

Mendez-Urena, M. ^{[10
]}

Lopez, C. ^{[11
]}

Garcia-Paredes, B. ^{[12
,13
]}

Gravalos, C. ^{[14
]}

Garcia-Garcia, T. ^{[15
]}

Falco, E. ^{[16
]}

Martin-Valades, J. I. ^{[17
]}

Gonzalez-Flores, E. ^{[18
]}

Navalon, M. ^{[19
]}

Diaz-Rubio, E. ^{[12
,13
]}

机构：

[1] Univ Cordoba, Maimonides Inst Biomed Res IMIBIC, Reina Sofia Hosp,Med Oncol, Spanish Canc Network RTICC,Inst Salud Carlos III, Cordoba, Spain

[2] Gregorio Maranon Hosp, Med Oncol, Madrid, Spain

[3] Hosp Univ Reg & Virgen de la Victoria, Med Oncol, Malaga, Spain

[4] Puerta de Hierro Hosp, Med Oncol, Madrid, Spain

[5] Univ Ramon & Cajal Hosp, Med Oncol, Madrid, Spain

[6] Univ Gen Hosp, Med Oncol, Valencia, Spain

[7] Costa del Sol Hosp, Med Oncol, Malaga, Spain

[8] Hosp Clin Santiago, Med Oncol, Santiago De Compostela, Spain

[9] Germans Trias & Pujol Hosp ICO, Med Oncol, Badalona, Spain

[10] Hosp Mostoles, Med Oncol, Mostoles, Spain

[11] Marques de Valdecilla Hosp, Med Oncol, Santander, Spain

[12] HC San Carlos, Madrid, Spain

[13] Inst Carlos III, Spanish Minist Sci & Innovat, Med Madrid, Ctr Affiliated Red Temat Invest Cooperat RD06 002, Madrid, Spain

[14] Doce Octubre Hosp, Med Oncol, Madrid, Spain

[15] Morales Meseguer Hosp, Med Oncol, Murcia, Spain

[16] Son Llatzer Hosp, Med Oncol, Palma De Mallorca, Spain

[17] Fdn Jimenez Diaz, Med Oncol, E-28040 Madrid, Spain

[18] Virgen de las Nieves Hosp, Med Oncol, Granada, Spain

[19] Complejo Asistencial, Med Oncol, Zamora, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31044-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2122

引用

页码：S371 / S372

页数：2

共 50 条

[1] First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
Aranda, E.
Garcia-Alfonso, P.
Benavides, M.
Sanchez Ruiz, A.
Guillen-Ponce, C.
Safont, M. J.
Alcaide, J.
Gomez, A.
Lopez, R.
Manzano, J. L.
Mendez Urena, M.
Sastre, J.
Rivera, F.
Gravalos, C.
Garcia, T.
Martin-Valades, J. I.
Falco, E.
Navalon, M.
Gonzalez Flores, E.
Garcia Tapiador, A. Ma
Lopez Munoz, A. Ma
Barrajon, E.
Reboredo, M.
Garcia Teijido, P.
Viudez, A.
Cardenas, N.
Diaz-Rubio, E.
EUROPEAN JOURNAL OF CANCER, 2018, 101 : 263 - 272
[2] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
Eiji Oki
Yasunori Emi
Takeharu Yamanaka
Hiroyuki Uetake
Kei Muro
Takao Takahashi
Takeshi Nagasaka
Etsuro Hatano
Hitoshi Ojima
Dai Manaka
Tetsuya Kusumoto
Yu Katayose
Toshiyoshi Fujiwara
Kazuhiro Yoshida
Michiaki Unno
Ichinosuke Hyodo
Naohiro Tomita
Kenichi Sugihara
Yoshihiko Maehara
British Journal of Cancer, 2019, 121 : 222 - 229
[3] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
Oki, Eiji
Emi, Yasunori
Yamanaka, Takeharu
Uetake, Hiroyuki
Muro, Kei
Takahashi, Takao
Nagasaka, Takeshi
Hatano, Etsuro
Ojima, Hitoshi
Manaka, Dai
Kusumoto, Tetsuya
Katayose, Yu
Fujiwara, Toshiyoshi
Yoshida, Kazuhiro
Unno, Michiaki
Hyodo, Ichinosuke
Tomita, Naohiro
Sugihara, Kenichi
Maehara, Yoshihiko
BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
[4] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
Martinelli, E.
Macarulia, T.
Vega-Villegas, E.
Rodriguez-Braun, E.
Ciardiello, F.
Ramos, F.
Rivera, F.
Stroh, C.
Nippgen, J.
Cervantes, A.
Baselga, J.
Tabernero, J.
ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
[5] Results of a phase II trial of cetuximab plus XELIRI as first-line therapy of patients with advanced and/or metastatic colorectal cancer
Cartwright, T. H.
Kuefler, P.
Cohn, A.
Hyman, W.
Yoffe, M.
Boehm, K. A.
Ilegbodu, D.
Asmar, L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[6] Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
Assenat, Eric
Desseigne, Francoise
Thezenas, Simon
Viret, Frederic
Mineur, Laurent
Kramar, Andrew
Samalin, Emmanuelle
Portales, Fabienne
Bibeau, Frederic
Crapez-Lopez, Evelyne
Bleuse, Jean Pierre
Ychou, Marc
ONCOLOGIST, 2011, 16 (11): : 1557 - 1564
[7] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
Cartwright, Thomas
Kuefler, Paul
Cohn, Allen
Hyman, William
Berger, Maury
Richards, Donald
Vukelja, Svetislava
Nugent, John E.
Ruxer, Robert L., Jr.
Boehm, Kristi A.
Asmar, Lina
CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
[8] RANDOMIZED PHASE II STUDY EVALUATING UFOX PLUS CETUXIMAB VERSUS FOLFOX4 PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER: FUTURE
Douillard, Jean-Yves
Zemelka, Tomasz
Fountzilas, Georgios
Barone, Carlo
Schlichting, Michael
Eggleton, S. Peter
Srimuninnimit, Vichien
ANNALS OF ONCOLOGY, 2012, 23 : 11 - 12
[9] Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer
Moosmann, Nicolas
Heinemann, Volker
CLINICAL COLORECTAL CANCER, 2008, 7 (02) : 110 - 117
[10] Efficacy and safety of XELIRI plus cetuximab versus XELOX plus cetuximab in first-line treatment of metastatic colorectal cancer (mCRC)
Ocvirk, J.
Boc, M.
Rebersek, M.
Mesti, T.
Ebert, M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →